Hormone replacement therapy after endometrial cancer

Menopause International

Volumn 18, Issue 4, 2012, Pages 134-138

  Manley, K ^a   Edey, K ^a   Braybrooke, J ^b   Murdoch, J ^a  

^a ST MICHAEL'S HOSPITAL   (United Kingdom)

^b BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

Author keywords

Alternative therapies; cHRT; Endometrial cancer; ERT; Progesterone replacement

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTRIOL; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; MEGESTROL ACETATE; PLACEBO; TAMOXIFEN; TESTOSTERONE; VITAMIN D;

ABDOMINAL HYSTERECTOMY; ACTAEA RACEMOSA; AEROBIC EXERCISE; ALTERNATIVE MEDICINE; ANDROGEN THERAPY; CANCER PATIENT; CANCER RISK; CANCER SURGERY; CEREBROVASCULAR ACCIDENT; COLON CANCER; COLORECTAL CANCER; DRUG MEGADOSE; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM SARCOMA; ESTROGEN THERAPY; GINSENG; HEART INFARCTION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HORMONE SUBSTITUTION; HUMAN; LIBIDO DISORDER; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LOW DRUG DOSE; META ANALYSIS (TOPIC); MINIMAL RESIDUAL DISEASE; PATIENT SATISFACTION; POSTMENOPAUSE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALPINGOOOPHORECTOMY; SMOKING CESSATION; THROMBOSIS; TOPICAL TREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; VAGINA RING; VAGINAL DRYNESS;

ANDROGENS; ENDOMETRIAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE, PREMATURE; TESTOSTERONE; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 84872518988     PISSN: 17540453     EISSN: 17540461     Source Type: Journal    
DOI: 10.1258/mi.2012.012024     Document Type: Review

References (44)

1. Cancerstats 2007. Endometrial Cancer. Cancer Research UK
2. Fornander T, Rutqvist LE, Cedermark B, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989;1:117-20
3. Bernstein L, Deapen D, Cerhan JR, et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 1999;91:1654-62
4. Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999;81:214-8
5. Dunlop MG, Farrington SM, Carothers AD, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997;6:105-10
6. Vasen HF, Stormorken A, Menko FH, et al. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer patients. J Clin Oncol 2001;19:4074-80
7. Hulley S, Grady D, Bush T, et al. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in the post menopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) research group. JAMA 1998;280:605-13
8. http://www.millionwomenstudy.org/ (last checked 30 April 2012)
9. Anderson GL, Judd HL, Kaunitz AM, et al. Women's Health Initiative Investigators. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomised trial. JAMA 2003;290:1739-48
10. Shapiro S, Farmer RD, Seaman H, Stevenson JC, Mueck AO. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: Part 1. The collaborative reanalysis. J Fam Plann Reprod Health Care 2011;37:103-9
11. Shapiro S, Farmer RD, Mueck AO, Seaman H, Stevenson JC. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: Part 2. The Women's Health Initiative: estrogen plus progestogen. J Fam Plann Reprod Health Care 2011;37:165-72
12. Shapiro S, Farmer RD, Mueck AO, Seaman H, Stevenson JC. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: Part 3. The Women's Health Initiative: unopposed estrogen. Fam Plann Reprod Health Care 2011;37:225-30
13. Shapiro S, Farmer RD, Stevenson JC, Burger HG, Mueck AO. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies. Part 4. The Million Women Study. Fam Plann Reprod Health Care 2012;38:102-9
14. Lethaby A, Suckling J, Barlow D, Farquhar CM, Jepson RG, Roberts H. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2004;(3):CD000402
15. Epstein E, Lindqvist PG, Olsson H. A population-based cohort study on the use of hormone treatment and endometrial cancer in southern Sweden. Int J Cancer 2009;125:421-5
16. Sturdee DW, Ulrich LG, Barlow DH, Wells M, et al. The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy. Br J Obstet Gynecol 2000;107:1392-400
17. Barakat RR, Bundy BN, Spirtos NM, Bell J, Mannel RS, Gynecologic Oncology Group Study. Randomised double blind trial of estrogen replacement therapy versus placebo in stage I or stage II endometrial carcinoma: a Gynecologic Oncology Study Group. J Clin Oncol 2006;24:587-92
18. Creasman WT, Henderson D, Hinshaw W, Clark-Pearson PL. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 1986;67:326-30
19. Lee RB, Burke TW, Park RC. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 1990;36:189-91
20. Chapman JA, DiSaia PJ, Osann K, et al. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 1996;175:1195-200
21. Suriano KA, McHale M, Mc Laren CE, et al. Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet Gynecol 2001;97:555-60
22. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994;331:347-52
23. Goodwin JW, Green SJ, Moinpour CM, et al. Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626. J Clin Oncol 2008;26:1650-6
24. Ayhan A, Taskiran C, Simsek S, Sever A. Does immediate hormone replacement therapy affect the oncologic outcome in endometrial cancer survivors? Int J Gynecol Cancer 2006;16:805-8
25. Van Haaften M, Donker GH, Sie-Go DM, Haspels AA, Thijssen JH. Biochemical and histological effects of vaginal estriol and estradiol applications on the endometrium, myometrium and vagina of postmenopausal women. Gynecol Endocrinol 1997;11:175-85
26. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006;18:CD001500
27. Kendall A, Dowsett M, Folkerd E, Smith I. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006;17:584-7
28. Simon J, Nachtigall L, Ulrich LG, Eugster-Hausmann M, Gut R. Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstet Gynecol 2010;116:876-83
29. Chu MC, Mor G, Lim C, Zheng W, Parkash V, Schwartz PE. Low grade endometrial stromal sarcoma: hormonal aspects. Gynecol Oncol 2003;90:170-6
30. Hubayter Z, Simon JA. Testosterone therapy for sexual dysfunction in postmenopausal women. Climacteric 2008;11:181-91
31. Watts NB, Notelovitz M, Timmons MC, Addison WA, Wiita B, Downey LJ. Comparison of oral estrogens and estrogens plus androgens on bone mineral density, menopausal symptoms and lipid-lipoprotein profiles in surgical menopause. Obstet Gynecol 1995;85:529-37
32. Barrett-Connor E, Young R, Notelovitz M, et al. A two year double blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women: effects on bone mineral density, symptoms and lipid profiles. J Reprod Med 1999;44:1012-20
33. Hickok LR, Toomey C, Speroff L. A comparison of esterified oestrogens with and without methyltestosterone: effects on endometrial histology and serum lipoproteins in post-menopausal women. Obstet Gynecol 1993;82:919-24
34. Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophrectomy. N Engl J Med 2000;343:682-8
35. Buster JE, Kingsberg SA, Aguirre O, et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomised trial. Obstet Gynecol 2005;105:944-52
36. http://www.nhs.uk/Conditions/vitamins-minerals/Pages/Vitamin-D.aspx (last checked 30 April 2012)
37. http://www.sacn.gov.uk/meetings/working-groups/vitamin/index.html (last checked 30 April 2012)
38. Royal College of Obstetricians and Gynaecologists Scientific Advisory Committee. Alternatives to HRT for management of symptoms of menopause. RCOG, London: 2010
39. Writing Group for the British Menopause Society Council, Pitkin J, Rees MC, Gray S, et al . Non-estrogen based treatments for menopausal symptoms. Menopause International 2008;14:88-90
40. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in the management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059-63
41. Freeman EW, Guthrie Ka, Caan B, et al. Efficacy of citalopram for hot flashes in healthy menopausal women. JAMA 2011;305:267-74
42. Lethaby AE, Brown J, Marjoribanks J, Kronenberg F, Roberts H, Eden J. Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2007;17:CD001395
43. Alternative and Complementary Therapies (2007). British Menopause Society Consensus Statement
44. Nelson HD, Vesco KK, Haney E, et al. Non-hormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006; 295:2057-71